Century Therapeutics, Inc. (IPSC)
NASDAQ:IPSC
Want to see IPSC full AI Analyst Report?
IPSC Stock Chart & Stats
$2.60
<$0.01(0.47%)
At close: 4:00 PM EST
$2.60
<$0.01(0.47%)
Day’s Range― - ―
52-Week Range$0.44 - $3.04
Previous CloseN/A
Volume712.78K
Average Volume (3M)1.58M
Market Cap
$399.73M
Enterprise Value$173.90M
Total Cash (Recent Filing)$117.11M
Total Debt (Recent Filing)$43.56M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
May 20, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding180,057,280
10 Day Avg. Volume1,411,010
30 Day Avg. Volume1,575,947
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit1.75
Enterprise Value/Ebitda-89.68
Forecast
1Y Price Target
$5.80Price Target Upside123.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing ReadinessSecuring a GMP master cell bank with immune-evasion edits and producing cryopreserved, quality-controlled beta cell products strengthens manufacturing readiness and reduces execution risk for scaling therapy supply.
Preclinical EfficacyPreclinical data showing CNTY-813 delivers sustained glycemic control and long-term cell persistence in animal models supports significant upside if similar effects are observed in human trials.
Regulatory PathwayConstructive interactions with the FDA combined with ongoing IND-enabling studies indicate a clearer regulatory pathway toward initiating clinical testing for the lead program.
Bears Say
Clinical Trial Design UncertaintyUndisclosed clinical trial design creates uncertainty about how initial clinical success will be measured, making it difficult for investors to gauge near-term program prospects.
Endpoint Clarity RiskUnclear definition of study endpoints increases the risk of regulatory disagreement or protocol revisions, which could lead to trial redesigns or added costs.
Investor Interpretation And VolatilityAmbiguity around trial metrics may amplify stock volatility as investors could struggle to interpret early results and adjust expectations accordingly.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics, Inc.’s price range in the past 12 months?
Century Therapeutics, Inc. lowest stock price was $0.43 and its highest was $3.04 in the past 12 months.
What is Century Therapeutics, Inc.’s market cap?
Century Therapeutics, Inc.’s market cap is $399.73M.
When is Century Therapeutics, Inc.’s upcoming earnings report date?
Century Therapeutics, Inc.’s upcoming earnings report date is May 20, 2026 which is in 23 days.
How were Century Therapeutics, Inc.’s earnings last quarter?
Century Therapeutics, Inc. released its earnings results on Mar 12, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.04.
Is Century Therapeutics, Inc. overvalued?
According to Wall Street analysts Century Therapeutics, Inc.’s price is currently Undervalued.
Does Century Therapeutics, Inc. pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
What is Century Therapeutics, Inc.’s EPS estimate?
Century Therapeutics, Inc.’s EPS estimate is -0.16.
How many shares outstanding does Century Therapeutics, Inc. have?
Century Therapeutics, Inc. has 180,057,280 shares outstanding.
What happened to Century Therapeutics, Inc.’s price movement after its last earnings report?
Century Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -8.425%.
Which hedge fund is a major shareholder of Century Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (123.08% Upside)
$5.80 (123.08% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $45.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
378.82%
12-Months-Change
Fundamentals
Return on Equity
-4.88%
Trailing 12-Months
Asset Growth
-36.67%
Trailing 12-Months
Company Description
Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.80
▲(123.08% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
3.49% Insiders
1.27% Mutual Funds
5.08% Other Institutional Investors
86.98% Public Companies and
Individual Investors